Quarterly ResultAug 5, 2026, 07:21 AM
Charles River Q2 Revenue $1.00B; Raises 2026 Non-GAAP EPS Guidance
AI Summary
Charles River Laboratories reported second-quarter 2026 revenue of $1.00 billion, a 2.7% decrease, but achieved 0.1% organic revenue growth, its highest since Q3 2023. The company reported a GAAP loss per share of $(0.03) due to divestiture-related losses, while non-GAAP EPS was $3.02. Charles River increased its full-year 2026 guidance for both revenue and non-GAAP earnings per share, driven by improving demand in the DSA segment and strong performance in Manufacturing.
Key Highlights
- Q2 2026 revenue was $1.00 billion, a 2.7% decrease from Q2 2025.
- Organic revenue growth reached 0.1%, the highest level since Q3 2023.
- GAAP loss per share was $(0.03), primarily due to divestiture losses.
- Non-GAAP diluted EPS was $3.02, a 3.2% decrease from Q2 2025.
- Increased 2026 organic revenue guidance to 0.0%-1.0% (from -1.5% to -0.5%).
- Increased 2026 non-GAAP EPS guidance to $11.15-$11.45 (from $10.80-$11.30).
- Repurchased $100 million of common stock in Q2 2026 at $174 per share.
- Completed divestitures of certain European Discovery Services sites, CDMO, and Cell Solutions businesses.